SightfileU.S. market data from official filings

Companies › XTLB

XTL BIOPHARMACEUTICALS LTD (XTLB)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001023549 · EDGAR filings · Updated 2026-07-21

XTL BIOPHARMACEUTICALS LTD (XTLB) has 6 institutional managers reporting positions valued at $175.4K per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional managers
6
Reported 13F value
$175.4K
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, XTL BIOPHARMACEUTICALS LTD has 6 institutional holders.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-06-30 (recurring since 2025-04-30) — source filing. The authoritative details are those stated in the filing itself.

Related companies

Biorestorative Therapies Inc (BRTX) · ENvue Medical Inc (FEED) · MATINAS BIOPHARMA HLDGS INC (MTNB) · Genprex Inc (GNPX) · CURANEX PHARMACEUTICALS INC (CURX) · HCW Biologics Inc (HCWB)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.